Key result
Subchronic, but not acute, daunorubicin cardiomyopathy in rats down-regulated the expression of cytokines and stem cell markers, reflecting impaired stem cell migration and homing.
Why the study?
Does daunorubicin cardiotoxicity alter the expression of cytokines involved in stem cell migration and homing in rat models of acute and subchronic cardiomyopathy?
Does daunorubicin cardiotoxicity alter the expression of cytokines involved in stem cell migration and homing in rat models of acute and subchronic cardiomyopathy?
Daunorubicin down-regulates cytokines and stem cell markers in subchronic but not acute cardiomyopathy, suggesting impaired tissue repair mechanisms.
Daunorubicin cytokine changes in rat models warrant caution in translation; leaves open the role of stem cell homing in clinical anthracycline cardiotoxicity.
We tested the hypothesis that daunorubicin (DAU) cardiotoxicity alters expression of cytokines involved in stem cell migration and homing. Male Wistar rats were treated with daunorubicin to induce acute DAU cardiomyopathy (6 × 3 mg/kg, i.p., every 48 hr, DAU-A) or subchronic DAU cardiomyopathy (15 mg/kg, i.v., DAU-C). The left ventricle was catheterized. The animals were killed 48 hr (DAU-A) and 8 weeks (DAU-C) after the last dose of DAU. Expression of foetal genes (Nppa, Nppb), isomyosins (Myh6, Myh7), sources of oxidative stress (Abcb8, gp91phox), cytokines (Sdf-1, Cxcr4, Scf, Vegf, Hgf, Igf-1), markers of cardiac progenitor (c-kit, Atnx-1), endothelial progenitor (CD34, CD133) and mesenchymal (CD44, CD105) stem cells were determined by qRT-PCR in left ventricular tissue. Reduced body-weight, decreased left ventricular weight and function, and elevated Nppa, Nppb, Myh7 were observed in both models. Myh6 decreased only in DAU-C, which had a 35% mortality. Up-regulated gp91phox and down-regulated Abcb8 in DAU were present only in DAU-C where we observed markedly decreased expressions of Scf and Vegf as well as expressions of stem cell markers. Down-regulation of cytokines and stem cell markers may reflect impaired chemotaxis, migration and homing of stem cells and tissue repair in the heart in subchronic but not acute model of DAU cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Srankova et al. (2016) studied Daunorubicin cardiomyopathy. Daunorubicin was evaluated on Expression of cytokines and stem cell markers. Subchronic, but not acute, daunorubicin cardiomyopathy in rats down-regulated the expression of cytokines and stem cell markers, reflecting impaired stem cell migration and homing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: